NZ603895A - Novel phosphodiesterase inhibitors - Google Patents

Novel phosphodiesterase inhibitors

Info

Publication number
NZ603895A
NZ603895A NZ603895A NZ60389511A NZ603895A NZ 603895 A NZ603895 A NZ 603895A NZ 603895 A NZ603895 A NZ 603895A NZ 60389511 A NZ60389511 A NZ 60389511A NZ 603895 A NZ603895 A NZ 603895A
Authority
NZ
New Zealand
Prior art keywords
compound
difluoromethoxy
phosphodiesterase inhibitors
novel phosphodiesterase
benzodioxole
Prior art date
Application number
NZ603895A
Other languages
English (en)
Inventor
Simon Feldbaek Nielsen
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of NZ603895A publication Critical patent/NZ603895A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
NZ603895A 2010-06-24 2011-06-24 Novel phosphodiesterase inhibitors NZ603895A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35820910P 2010-06-24 2010-06-24
PCT/DK2011/000069 WO2011160632A1 (en) 2010-06-24 2011-06-24 Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
NZ603895A true NZ603895A (en) 2014-10-31

Family

ID=44351701

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ603895A NZ603895A (en) 2010-06-24 2011-06-24 Novel phosphodiesterase inhibitors

Country Status (29)

Country Link
US (3) US8980905B2 (cg-RX-API-DMAC7.html)
EP (2) EP2585469B1 (cg-RX-API-DMAC7.html)
JP (2) JP6174997B2 (cg-RX-API-DMAC7.html)
KR (1) KR101864578B1 (cg-RX-API-DMAC7.html)
CN (1) CN102958937B (cg-RX-API-DMAC7.html)
AU (1) AU2011269429B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012032813B1 (cg-RX-API-DMAC7.html)
CA (1) CA2802895C (cg-RX-API-DMAC7.html)
CY (2) CY1117862T1 (cg-RX-API-DMAC7.html)
DK (2) DK3070091T3 (cg-RX-API-DMAC7.html)
ES (2) ES2584055T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20160919T1 (cg-RX-API-DMAC7.html)
HU (2) HUE030081T2 (cg-RX-API-DMAC7.html)
IL (1) IL223329A (cg-RX-API-DMAC7.html)
LT (2) LT3070091T (cg-RX-API-DMAC7.html)
MX (1) MX2012014131A (cg-RX-API-DMAC7.html)
MY (1) MY157481A (cg-RX-API-DMAC7.html)
NZ (1) NZ603895A (cg-RX-API-DMAC7.html)
PL (2) PL2585469T3 (cg-RX-API-DMAC7.html)
PT (2) PT2585469T (cg-RX-API-DMAC7.html)
RS (2) RS55104B1 (cg-RX-API-DMAC7.html)
RU (1) RU2583787C2 (cg-RX-API-DMAC7.html)
SG (1) SG186140A1 (cg-RX-API-DMAC7.html)
SI (2) SI2585469T1 (cg-RX-API-DMAC7.html)
TR (1) TR201909709T4 (cg-RX-API-DMAC7.html)
TW (1) TWI507410B (cg-RX-API-DMAC7.html)
UA (1) UA109140C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011160632A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201209031B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014083099A1 (en) * 2012-11-30 2014-06-05 Leo Pharma A/S A method of inhibiting the expression of il-22 in activated t-cells
PL3157930T3 (pl) * 2014-06-23 2019-04-30 Leo Pharma As Sposoby wytwarzania związków heterocyklicznych 1,3-benzodioksolu
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
PT3390407T (pt) * 2015-12-18 2023-11-03 Union Therapeutics As Métodos para a preparação de compostos heterocíclicos de 1,3-benzodioxole
MX394835B (es) 2017-06-20 2025-03-24 Union Therapeutics As Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
PT3724196T (pt) 2017-12-15 2023-01-13 Union Therapeutics As Azetidina di-hidrotienopiridinas substituídas e a sua utilização como inibidores de fosfodiesterase
CN120097995A (zh) 2018-05-21 2025-06-06 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
EA202191955A1 (ru) * 2019-01-15 2021-10-07 Юнион Терапьютикс А/С Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
JP7530420B2 (ja) * 2019-07-24 2024-08-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッド がんの治療のためのｅｚｈ２阻害併用療法
CN112552276B (zh) * 2019-09-25 2023-03-21 中国科学院上海药物研究所 苯并氧杂卓-5-酮类化合物及其制备方法和用途
EP4313043A1 (en) 2021-03-22 2024-02-07 UNION therapeutics A/S Treatment of hidradenitis suppurativa with orismilast
GB202205715D0 (en) 2022-04-19 2022-06-01 Union Therapeutics As Treatment of neutrophilic dermatoses
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ290266B6 (cs) * 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
GB9507297D0 (en) 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
DK0771794T3 (da) 1995-05-19 2006-09-11 Kyowa Hakko Kogyo Kk Oxygenholdige heterocykliske forbindelser
NZ332340A (en) * 1996-05-20 2000-04-28 Darwin Discovery Ltd 4-(aryl or heteroaryl) substituted benzofurancarboxamide derivatives and medicaments
CA2272327A1 (en) 1996-11-19 1998-05-28 Kyowa Hakko Kogyo Co., Ltd. Oxygen-containing heterocyclic compounds
JP2005060375A (ja) * 2003-07-28 2005-03-10 Kyowa Hakko Kogyo Co Ltd 含酸素複素環化合物
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
AU2005315319B2 (en) * 2004-12-17 2011-07-07 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
UA98639C2 (en) * 2007-02-28 2012-06-11 Лео Фарма А/С Phosphodiesterase inhibitors
MX2009009238A (es) * 2007-02-28 2009-09-08 Leo Pharma As Nuevos inhibidores de fosfodiesterasa.
EP2794603B1 (en) * 2011-12-21 2016-06-15 Leo Pharma A/S [1,2,4]triazolopyridines and their use as phospodiesterase inhibitors

Also Published As

Publication number Publication date
US9637499B2 (en) 2017-05-02
CY1117862T1 (el) 2017-05-17
BR112012032813B1 (pt) 2022-02-01
JP6174997B2 (ja) 2017-08-02
PT3070091T (pt) 2019-07-22
PL3070091T3 (pl) 2019-09-30
JP2016164168A (ja) 2016-09-08
KR101864578B1 (ko) 2018-06-07
SI2585469T1 (sl) 2016-11-30
ES2584055T3 (es) 2016-09-23
SI3070091T1 (sl) 2019-08-30
SG186140A1 (en) 2013-01-30
JP2013529602A (ja) 2013-07-22
IL223329A (en) 2017-01-31
TW201206940A (en) 2012-02-16
IL223329A0 (en) 2013-02-03
AU2011269429A1 (en) 2012-12-20
CN102958937A (zh) 2013-03-06
EP3070091A1 (en) 2016-09-21
UA109140C2 (uk) 2015-07-27
HUE044301T2 (hu) 2019-10-28
TWI507410B (zh) 2015-11-11
MY157481A (en) 2016-06-15
PT2585469T (pt) 2016-08-29
LT2585469T (lt) 2016-10-10
RS58945B1 (sr) 2019-08-30
US8980905B2 (en) 2015-03-17
HRP20160919T1 (hr) 2016-10-07
CA2802895C (en) 2019-05-21
DK2585469T3 (en) 2016-08-29
AU2011269429B2 (en) 2015-07-09
HRP20191136T1 (hr) 2019-09-20
RU2583787C2 (ru) 2016-05-10
HK1182699A1 (zh) 2013-12-06
RU2013103079A (ru) 2014-07-27
DK3070091T3 (da) 2019-07-08
TR201909709T4 (tr) 2019-07-22
RS55104B1 (sr) 2016-12-30
MX2012014131A (es) 2013-01-29
US20150111915A1 (en) 2015-04-23
HUE030081T2 (en) 2017-04-28
ES2733092T3 (es) 2019-11-27
US20130123291A1 (en) 2013-05-16
CN102958937B (zh) 2016-03-30
EP2585469B1 (en) 2016-05-25
CA2802895A1 (en) 2011-12-29
WO2011160632A1 (en) 2011-12-29
US20160022657A1 (en) 2016-01-28
LT3070091T (lt) 2019-07-25
ZA201209031B (en) 2014-02-26
US9273064B2 (en) 2016-03-01
PL2585469T3 (pl) 2017-07-31
EP3070091B1 (en) 2019-04-17
EP2585469A1 (en) 2013-05-01
BR112012032813A2 (pt) 2016-11-08
KR20130038341A (ko) 2013-04-17
CY1122201T1 (el) 2020-11-25

Similar Documents

Publication Publication Date Title
NZ603895A (en) Novel phosphodiesterase inhibitors
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
PH12015500441A1 (en) Crystalline forms of 1-(5`-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3`h-spiro[azetidine-3,1`-isobenzofuran]-1-yl)-2-(methylsulfonyl)ethanone
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
EP3311818A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
NZ596579A (en) Bace inhibitors
MA32604B1 (fr) Composes organiques
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
WO2010066684A3 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
TW200800975A (en) New compounds 2
MX2012002179A (es) Compuestos heterociclicos de oxima.
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MY162555A (en) Pyrimidine derivatives having human neutrophil elastase inhibitory properties, and their use in therapy
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA200900913A1 (ru) Производное триазола в качестве ингибитора hsp90
WO2009026176A3 (en) Antiinfective flavononol compounds and methods of use thereof
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
UA107583C2 (ru) Спироциклические нитрилы как ингибиторы протеазы
CL2008003854A1 (es) Compuestos derivados de 2-bencilpiridazinona, inhibidores, reguladores y/o moduladores de met-quinasa; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de un tumor solido, de la sangre o del sistema inmune; kit farmaceutico que comprende una cantidad de dicho compuesto.
EA201100872A1 (ru) Производные хиназолинамида
WO2012046030A3 (en) Phosphodiesterase inhibitors
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
MX2007007103A (es) Derivados espiro como inhibidores de lipoxigenasa.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2016 BY COMPUTER PACKAGES INC

Effective date: 20150602

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2017 BY COMPUTER PACKAGES INC

Effective date: 20160601

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2018 BY COMPUTER PACKAGES INC

Effective date: 20170531

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2019 BY COMPUTER PACKAGES INC

Effective date: 20180531

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2020 BY COMPUTER PACKAGES INC

Effective date: 20190531

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2021 BY COMPUTER PACKAGES INC

Effective date: 20200603

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2022 BY IP CENTRUM LIMITED

Effective date: 20210602

ASS Change of ownership

Owner name: UNION THERAPEUTICS A/S, DK

Effective date: 20210902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2023 BY IP CENTRUM LIMITED

Effective date: 20220526

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2024 BY IP CENTRUM LIMITED

Effective date: 20230531

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2025 BY IP CENTRUM LIMITED

Effective date: 20240531

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2026 BY IP CENTRUM LIMITED

Effective date: 20250613